X4 Pharmaceuticals (XFOR) Enterprise Value (2018 - 2025)
X4 Pharmaceuticals (XFOR) has disclosed Enterprise Value for 8 consecutive years, with -$69.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 28.52% year-over-year to -$69.6 million, compared with a TTM value of -$69.6 million through Sep 2025, up 28.52%, and an annual FY2024 reading of -$55.7 million, up 43.86% over the prior year.
- Enterprise Value was -$69.6 million for Q3 2025 at X4 Pharmaceuticals, down from -$39.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$39.2 million in Q2 2025 and bottomed at -$147.2 million in Q2 2024.
- Average Enterprise Value over 5 years is -$87.1 million, with a median of -$81.8 million recorded in 2021.
- The sharpest move saw Enterprise Value crashed 187.96% in 2023, then skyrocketed 73.36% in 2025.
- Year by year, Enterprise Value stood at -$81.8 million in 2021, then crashed by 48.82% to -$121.7 million in 2022, then increased by 18.49% to -$99.2 million in 2023, then surged by 43.86% to -$55.7 million in 2024, then decreased by 25.01% to -$69.6 million in 2025.
- Business Quant data shows Enterprise Value for XFOR at -$69.6 million in Q3 2025, -$39.2 million in Q2 2025, and -$40.3 million in Q1 2025.